Pain News and Research

Latest Pain News and Research

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

St. Jude Medical, Inc., a global medical device company, today announced that interim data demonstrated the company's EnligHTN renal denervation system is safe and effective for the treatment of resistant hypertension.

29 Aug 2012

Study looks at exercise habits among cancer patients

Numerous studies have shown the powerful effect that exercise can have on cancer care and recovery. For patients who have gone through breast or colon cancer treatment, regular exercise has been found to reduce recurrence of the disease by up to 50 percent.

29 Aug 2012

One in four women experience vulvar pain at some point in their lifetime

According to a study conducted by the University of Michigan, one in four women experience vulvar pain at some point in their lifetime. Like all medical concerns, vulvar pain causes both physical and mental stress. Additionally, vulvar pain can have an adverse effect on intimacy and relationships.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Major decline in early mortality for STEMI patients: French registries

Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.

28 Aug 2012

Views on Medicare: Rep. Kathy Hochul's campaign; Ryan's vision; Wyden's role

Kathy Hochul is a young, first-term Democratic congresswoman fighting for her political life in a solidly Republican district outside Buffalo, N.Y. Unlike most of that liberal state, this is Romney country; a poll last week showed the GOP candidate ahead of President Obama in her district by a whopping 12 points.

28 Aug 2012

Community-based pharmacists could provide added resource in identifying knee OA

Canadian researchers have determined that community-based pharmacists could provide an added resource in identifying knee osteoarthritis (OA). The study, published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), represents the first evidence supporting a collaborative approach to managing knee OA.

28 Aug 2012

Researchers develop glue mixture that may reduce risks after laser vision correction surgery

Kansas State University researchers have developed a glue mixture that may reduce risks after laser vision correction surgery.

28 Aug 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

RBC Life Sciences, Inc. announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

CardioDx completes two-tranche equity financing

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the completion of a $58 million two-tranche equity financing.

27 Aug 2012

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

27 Aug 2012

PEI adjuvant improves effect of vaccines against flu, HIV and herpes

Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice.

26 Aug 2012

Conifer Health to provide comprehensive revenue cycle management operations for TAH

Conifer Health Solutions, a leader in business process management solutions for healthcare providers, has reached an agreement to provide comprehensive revenue cycle management operations for Titusville Area Hospital (TAH) of Titusville, Pennsylvania.

26 Aug 2012